Chemical Structure (Xofluza 01)
Xofluza Granule, For Solution
Product Images NDC 50242-583
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Xofluza (NDC 50242-583). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Chemical Structure (Xofluza 02)
Chemical Structure (Xofluza 03)
Xofluza® is an oral suspension medication containing 2 mg baloxavir marboxil per mL after constitution, with a total usable volume of 20mL. It is taken as a single one-time dose and should be used before the suspension expires. There are no preservatives in the medication, and the appropriate measuring device should be used to ensure the correct total prescribed dose. Any unused portion should be discarded.*
Principal Display Panel (2x20 mg tablets (40 mg single dose))
Xofluza® is a medication available in tablet form containing 40mg of baloxavir marboxil. It is typically administered as a single, one-time dose. The National Drug Code (NDC) for Xofluza® is 50242-860-01. The instructions recommend taking the tablet from this package. However, the meaning of "ROHW, Lift Here H, Genentech 3" is not clear from this text.*
Principal Display Panel (2x40 mg tablets (80 mg single dose))
Xofluza® is a medication in tablet form with a total dose of 80mg per tablet. The usual method of consumption involves taking a single, one-time dose after opening the package. The medication is manufactured by Genentech and is available under NDC 50242-877-01.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
